CLSPN and familial pancreatic carcinoma: Notably, we found that celastrol treatment mediated the reduction of m6A levels of Claspin and Bcl-2 mRNA by downregulating METTL3, leading to the degradation of Claspin and Bcl-2 mRNA in pancreatic cancer cells.